

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1548)

GRANT OF SHARE OPTIONS AND GRANT OF RESTRICTED SHARES

The board (the “**Board**”) of directors (the “**Directors**”) of Genscript Biotech Corporation (the “**Company**”) announces that, on 29 August 2020, the Company has resolved to make grants of share options under the share option scheme adopted on 7 December 2015 (the “**Share Option Scheme**”) and restricted shares under the restricted share award scheme (the “**RSA Scheme**”) adopted on 22 March 2019.

THE GRANT OF SHARE OPTIONS

This section of the announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board is pleased to announce that on 29 August 2020 (the “**Date of Grant**”), 720,000 share options (the “**Option(s)**”) to subscribe for an aggregate of 720,000 ordinary shares of US\$0.001 each of the Company (the “**Share(s)**”) were granted to selected grantees (the “**Option Grantee(s)**”), subject to acceptance of the Option Grantees, under the Share Option Scheme. Details of the Options granted are set out as follows:

Date of Grant:	29 August 2020
Exercise price of Options granted:	HK\$15.040 per Share
Number of Options granted:	720,000 Options
Closing price of the Shares on the trading date immediately preceding the Date of Grant:	HK\$14.50 per Share

Average closing price per Share for
the five business days immediately
preceding the Date of Grant: HK\$15.040 per Share

Validity period of the Options: 29 August 2020 to 28 August 2025, both dates
inclusive

All of the total of 720,000 Options were granted to the following Grantees who are either the Director, chief executive and/or the substantial shareholder (as defined in the Listing Rules) of the Company, or an associate (as defined in the Listing Rules) of any of them:

Name of Grantee	Position in the Company	Number of Share Options Granted	Approximate % of the issued share capital of the Company as at the date of this announcement
Pan Yuexin 潘躍新	Non-Executive Director	60,000	0.0031%
Wang Jiafen 王佳芬	Non-Executive Director	270,000	0.0141%
Guo Hongxin 郭宏新	Independent Non-Executive Director	60,000	0.0031%
Dai Zumian 戴祖勉	Independent Non-Executive Director	60,000	0.0031%
Pan Jiuan 潘九安	Independent Non-Executive Director	270,000	0.0141%

The grant of Options to each of Mr. Pan Yuexin, Ms. Wang Jiafen, Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan has been approved by the independent non-executive Directors (excluding the independent non-executive director who is the Option Grantee) in accordance with Rule 17.04(1) of the Listing Rules.

The grant of 720,000 Options to the above Directors has been reviewed and approved by the remuneration committee of the Company.

Save as disclosed above, to the best knowledge, information and belief of the Board, none of the Grantees is a Director, chief executive or substantial shareholder of the Company, or an associate of any of them.

THE GRANT OF RESTRICTED SHARES

Reference is made to the announcement of the Company dated 22 March 2019 (the “**Announcement**”) in relation to the adoption of the RSA Scheme, a summary of the principal terms of which was set out in the Announcement. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

The Board is pleased to announce that on 29 August 2020, employees of the Company (the “**RSA Grantees**”) were granted 44,121 Restricted Shares (the “**RSA Shares**”), subject to acceptance of the RSA Grantees, pursuant to the RSA Scheme (the “**RSA Grant**”). Details of the RSA Grant are set out as follows:

Number of RSA Shares:	44,121 Restricted Shares, representing approximately 0.0023% of the issued share capital of the Company as at the date of this announcement
RSA Grantees:	Employees of the Company and to the best knowledge of the Directors, none of the RSA Grantees is a director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company or associate (as defined in the Listing Rules) of any of them
Date of Grant:	29 August 2020
Market price of the Shares:	The closing price per Share on the Stock Exchange on the trading date immediately preceding the Date of Grant of the Restricted Shares is HK\$14.50 per Share

The RSA Shares have been acquired by the Trustee through on-market transactions and are currently held by the Trustee in accordance with the Rules and the Trust Deed until the end of the relevant Vesting Date and be transferred to the RSA Grantees upon satisfaction of the relevant vesting conditions as may be specified by the Board at the time of making the RSA Grant. As no new Shares will be issued by the Company as a result of the RSA Grant, the RSA Grant will not result in any dilution effect on the shareholdings of existing shareholders of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman

Hong Kong, 30 August 2020

As at the date of this announcement, the executive Directors are Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* *For identification purposes only*